MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway

뉴스 본문을 불러오고 있어요.

MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway | 웨이프 WAPE

MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway

기사 요약

관련 종목

댓글 —